<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02957149</url>
  </required_header>
  <id_info>
    <org_study_id>16-001320</org_study_id>
    <nct_id>NCT02957149</nct_id>
  </id_info>
  <brief_title>Platelet Rich Plasma During Radical Prostatectomy</brief_title>
  <official_title>A Study Evaluating Intraoperative Application of Platelet-Rich Plasma to the Neurovascular Bundles During Nerve-Sparing Radical Prostatectomy: Initial Technical Description and Prospective Early Postoperative Outcomes Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthew Gettman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Can platelet rich plasma applied to nerve bundles at time of surgery help the nerve bundles
      heal? Subjects undergoing a Radical Prostatectomy who meet study inclusion/exclusion criteria
      will be consented to receive an intraoperative application of platelet-rich plasma, made from
      their own blood at the time of surgery, for application onto their neurovascular bundles in
      an effort to improve the healing process. Subjects will be followed for an additional 18
      months to determine the efficacy and safety of this procedure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in complete blood count (CBC)</measure>
    <time_frame>baseline, day after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects experiencing adverse events through 18 months</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in sexual function using International Index of Erectile Function (IIEF-5)</measure>
    <time_frame>baseline, 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urological Function using the Expanded Prostate Cancer Index composite (EPIC)</measure>
    <time_frame>baseline, 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Platelet Rich Plasma (PRP) Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The Autologous Platelet-Rich Plasma is concentrated in a device (Angel Concentrated Platelet Rich Plasma System) to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous Platelet-Rich Plasma</intervention_name>
    <description>Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The platelets are concentrated in a device to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.</description>
    <arm_group_label>Platelet Rich Plasma (PRP) Treatment</arm_group_label>
    <other_name>PRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Angel Concentrated Platelet Rich Plasma System</intervention_name>
    <arm_group_label>Platelet Rich Plasma (PRP) Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed, clinically localized prostatic adenocarcinoma

          -  Age 50 - 60 years

          -  Male gender

          -  Normal preoperative sexual function

          -  Normal urinary continence

          -  Regular sexual partner

        Exclusion Criteria:

          -  Unable or unwilling to provide informed consent

          -  Vulnerable study populations

          -  Active systemic infection

          -  Diabetes mellitus diagnosis

          -  Preexisting Erectile Dysfunction or urinary incontinence

          -  Metastatic or locally advanced prostatic adenocarcinoma on preoperative evaluation

          -  Men found grossly or pathologically to have locally advanced or metastatic disease at
             the time of radical prostatectomy

          -  An estimated blood loss of &gt; 750 mL at the time of radical prostatectomy

          -  Treatment prior to surgery with any form of hormones, anti-androgens or androgen
             deprivation therapy

          -  Use of an antidepressant, beta blocker or erectile dysfunction medication at the time
             of study screening

          -  Men without a regular sexual partner

          -  Use of aspirin or heparin 2 weeks before radical prostatectomy

          -  Need for use of aspirin or heparin for 2 weeks or more after radical prostatectomy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew T Gettman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tessa Kroeninger</last_name>
    <phone>507-538-6107</phone>
    <email>Kroeninger.tessa@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Doty Kathryn, 507-538-6151</last_name>
    <phone>507-538-6151</phone>
    <email>doty.kathryn@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Doty</last_name>
      <phone>507-538-6151</phone>
      <email>doty.kathryn@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2016</study_first_submitted>
  <study_first_submitted_qc>November 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2016</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Matthew Gettman</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

